NanoGhost News
7 articles
How to reduce cancer drug dosage a millionfold - ISRAEL21c
NanoGhost: Delivering the greatest things in the smallest packages
NanoGhost, a company founded by Prof. Marcelle Machluf and Yonatan Malca, is developing a drug-delivery technology based on adult stem cells. The technology, called NanoGhost, uses modified adult stem cells loaded with medicine to target cancer cells. The stem cells are emptied and shrunk to nano-size, creating nano-ghost vesicles that act as trojan horses to deliver medicine directly to the cancer cells. NanoGhost has raised $5 million in its seed round, with aMoon serving as a lead investor. The company aims to reach animal testing within a year and conduct clinical trials by 2023. The founders emphasize that there is still work to be done, but they believe the system works and will be effective in humans.
InvestmentExpand
Prof. Marcelle Machluf Is Adapting Nano-Ghost Research to Trap COVID-19 - American Technion Society
Technion Professor Marcelle Machluf has adapted her nano-ghost research to trap COVID-19. The companys growth is expected to be positive as a result of this research adaptation. The key theme of the article is research. The key issues discussed in the article are expansion and recruitment. The event described in the article does not have a specific date mentioned. The confidence level of the answer is 8.
Expand
Life Sciences Venture Fund aMoon Invests $5 Million in Cancer Drug Company
Israel-based life sciences, healthcare, and technology venture capital firm aMoon, together with an unnamed private investor, invested $5 million in cancer drug startup NanoGhosts. NanoGhosts turns stem cells into a drug delivery system that specifically targets cancerous tumors. The technology is based on the founders research at the Technion Israel Institute of Technology. NanoGhosts research has shown promising results in prolonging the survival of animals with cancer. AMoon is a venture capital firm founded in 2016 and its portfolio includes other healthcare and technology companies.
Investment
'Ghost' cell startup that targets deadliest cancers gets funding boost
aMoon, a health-tech fund, has made a $5 million investment in a new venture set up by Prof. Marcelle Machluf to develop her NanoGhost technology, which aims to shrink the deadliest forms of cancer by precisely targeting the tumors. The NanoGhost technology, developed by Machluf at the Technion-Israel Institute of Technology, uses mesenchymal stem cells to create nano-vehicles filled with anti-cancer drugs that are injected into the bloodstream and released directly into the tumors. Lab experiments have shown promising results in reducing tumor size. aMoons investment will support the commercialization of the technology.
Investment
Israeli Scientist Discusses Cancer Treatment - Jewish Exponent
Marcelle Machluf, the dean of biotechnology and food engineering at the Technion-Israel Institute of Technology, is working on an innovative cancer treatment called nanoghosts. Nanoghosts, a drug-delivery technology that uses adult stem cells to transport medicine directly to the tumor site, have already proven successful in treating various types of cancer in mice. The technology has won Machluf numerous honors and awards. The next step is to raise funds for the company and proceed to clinical trials. Machluf believes that nanoghosts have the potential to be a game changer in the field of cancer treatment, improving drug efficacy and reducing side effects. She also discusses her experiences as a woman and minority in the field of science and offers advice to others interested in pursuing STEM.
InvestmentExpand
https://www.jpost.com/HEALTH-SCIENCE/The-woman-behind-nanoghosts-552974
Prof. Marcelle Machluf, a scientist at the Technion-Israel Institute of Technology, had her medical articles initially rejected by journals but has since been recognized for her research on tissue engineering and cancer drug delivery. Her lab studies have shown that her modified stem cells called nanoghosts can kill every type of solid tumor. The rejection by journals was seen as a growth-negative impact on the company, but the subsequent recognition and publication of her work have had a growth-positive impact. The key theme of the article is the achievements and contributions of Prof. Marcelle Machluf in the field of medical research. The key issues discussed in the article are related to customers, as the article mentions the testing of her lab studies on patients in the next year or two. The date of the event described in the article is not specified. The confidence in the answer is 8.
Customers
